Shenyang Xingqi Pharmaceutical Co.,Ltd.

300573

CNE100002DV1

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 2025-12-12			5-day change	1st Jan Change
71.66 ^CNY	+0.87%		-2.45%	+43.77%

Dec. 08	Xingqi Pharmaceutical's 39 Products Stay in China's Insurance Drug Catalogue	MT
Oct. 28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI

Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Interim Cash Dividend on A Shares for 2025, Payable on 24 September 2025

Published on 09/16/2025 at 03:32 pm EDT

S&P Capital IQ

Shenyang Xingqi Pharmaceutical Co.,Ltd.

+0.87%

Shenyang Xingqi Pharmaceutical Co.,Ltd. at the Extraordinary General Meeting of 2025 on 15 September 2025 approved 2025 interim profit distribution plan of cash dividend per 10 A shares (tax included) of CNY 7.00000000. Record date: 23 September 2025; Ex-date: 24 September 2025; Payment date: 24 September 2025.

Latest news about Shenyang Xingqi Pharmaceutical Co.,Ltd.

Dec. 08	Xingqi Pharmaceutical's 39 Products Stay in China's Insurance Drug Catalogue	MT
Oct. 28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
Oct. 09	Shenyang Xingqi Pharmaceutical Gets China Clinical Trial Nod for Macular Edema Injection	MT
Sep. 16	Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Interim Cash Dividend on A Shares for 2025, Payable on 24 September 2025	CI
Aug. 28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Interim Cash Dividend for the Year 2025	CI
Aug. 27	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
Jun. 17	Xingqi Pharmaceutical Begins Phase Three Trial for Anesthetic Gel	MT
May. 30	Xingqi Pharmaceutical Says No Adverse Effects Seen in Phase 1 Eye Drops Trial	MT
May. 26	Shenyang Xingqi Pharmaceutical Co.,Ltd. announced that it expects to receive CNY 850 million in funding	CI
May. 15	Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Final Cash Dividend Plan on A Shares for 2024, Payable on 22 May 2025	CI
Apr. 28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
Apr. 22	Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Final Dividend for the Year 2024	CI
Apr. 20	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-10-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
24-09-22	Shenyang Xingqi Pharmaceutical Co.,Ltd.(XSEC:300573) added to FTSE All-World Index	CI
24-09-18	Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Interim Cash Dividend for the 2024	CI
24-08-29	Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Profit Distribution for First Half of 2024	CI
24-08-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-07-25	Xingqi Pharmaceutical Gets Nod to Trial Eye Drops; Shares Up 4%	MT
24-07-24	Xingqi Pharmaceutical Gets Nod to Register Bromfenac Sodium Eye Drops; Shares Down 3%	MT
24-05-21	Space Peptides announced that it has received funding from Humanwell Healthcare Co.,Ltd., Shenyang Xingqi Pharmaceutical Co.,Ltd., Xiamen Furuier Pharmaceutical Co., Ltd., Purple Knight Capital and other investors	CI
24-05-15	Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Cash Dividend for 2023, Payable May 22, 2024	CI
24-04-26	Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80%	MT
24-04-25	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
24-04-18	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Chart Shenyang Xingqi Pharmaceutical Co.,Ltd.

Duration

Period

Chart Shenyang Xingqi Pharmaceutical Co.,Ltd.

300573: Dynamic Chart

Company Profile

SHENYANG XINGQI PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of ophthalmic drugs. The Companyâs main products are ophthalmic prescription drugs, including corneal repairing drugs, anti-bacteria drugs, artificial tears, anti-inflammation drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. The Company mainly distributes its products within domestic market.

Employees

2,426

Sector

Pharmaceuticals

Calendar

Dec. 17 - Extraordinary Shareholders Meeting

More about the company